Compare Live Nation Entertainment, Inc. (LYV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Live Nation Entertainment, Inc. trades at $171.93 (market cap $39.92B), while State Street SPDR S&P Biotech ETF trades at $153.99 (market cap $10.11B). The key difference: Live Nation Entertainment, Inc. is far larger — about 3.9× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 1,982,609). Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LYV | XBI | |
|---|---|---|
Market Cap | $39.92B | $10.11B |
Volume | 1,982,609 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $188.46 | $169.55 |
52-Week Low | $125.61 | $104.99 |
Typical Hold Time | 72 Days | 38 Days |
Enterprise Value | $42.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $172.10, up 0.74% today, with a bullish technical signal and strong analyst support. Revenue grew to $25.20B in 2025, though net income margin narrowed to 1.96%. Recent news highlights robust fan demand and strategic partnerships, while the stock faces high valuation multiples and regulatory scrutiny.
Outlook remains positive with a consensus price target of $208.18, but risks include elevated P/E of 117.49, debt levels, and legal uncertainties. Earnings momentum is mixed, with Q2 2026 beating estimates but Q1 and Q4 2025 missing, underscoring execution challenges amid growth.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
